A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2) Meeting Abstract
| Authors: | Dumbrava, E. E.; Hanna, G. J.; Cote, G. M.; Stinchcombe, T.; Johnson, M. L.; Chen, C.; Devarakonda, S.; Shah, N.; Xu, F.; Doebele, R. C.; Gounder, M. M. |
| Abstract Title: | A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680304881 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS3165 |
| Notes: | Meeting Abstract: TPS3165 -- This meeting was also held virtually -- Source: Wos |
